CL2011001590A1 - Compuesto estaminico 2-metil-1-fenil-2-(piridin-2-il)propano-1-amina o su isomero s, antagonista de nmda; y su uso para la terapia de la depresion. - Google Patents
Compuesto estaminico 2-metil-1-fenil-2-(piridin-2-il)propano-1-amina o su isomero s, antagonista de nmda; y su uso para la terapia de la depresion.Info
- Publication number
- CL2011001590A1 CL2011001590A1 CL2011001590A CL2011001590A CL2011001590A1 CL 2011001590 A1 CL2011001590 A1 CL 2011001590A1 CL 2011001590 A CL2011001590 A CL 2011001590A CL 2011001590 A CL2011001590 A CL 2011001590A CL 2011001590 A1 CL2011001590 A1 CL 2011001590A1
- Authority
- CL
- Chile
- Prior art keywords
- pyridin
- amine
- methyl
- propane
- phenyl
- Prior art date
Links
- IFOJJUKSLKNAOM-UHFFFAOYSA-N 2-methyl-1-phenyl-2-pyridin-2-ylpropan-1-amine Chemical compound C=1C=CC=NC=1C(C)(C)C(N)C1=CC=CC=C1 IFOJJUKSLKNAOM-UHFFFAOYSA-N 0.000 title abstract 2
- 208000020401 Depressive disease Diseases 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title 1
- JCABFPBDEZEFKI-UHFFFAOYSA-N 1-(3-fluorophenyl)-2-methyl-2-pyridin-2-ylpropan-1-amine Chemical compound C=1C=CC=NC=1C(C)(C)C(N)C1=CC=CC(F)=C1 JCABFPBDEZEFKI-UHFFFAOYSA-N 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Confectionery (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14067308P | 2008-12-24 | 2008-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2011001590A1 true CL2011001590A1 (es) | 2012-06-22 |
Family
ID=42288011
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011001590A CL2011001590A1 (es) | 2008-12-24 | 2011-06-24 | Compuesto estaminico 2-metil-1-fenil-2-(piridin-2-il)propano-1-amina o su isomero s, antagonista de nmda; y su uso para la terapia de la depresion. |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US8013165B2 (enExample) |
| EP (2) | EP2391606A4 (enExample) |
| JP (1) | JP5491524B2 (enExample) |
| KR (1) | KR20110097996A (enExample) |
| CN (1) | CN102333762B (enExample) |
| AR (1) | AR074981A1 (enExample) |
| AU (1) | AU2009330745B2 (enExample) |
| BR (1) | BRPI0923476A2 (enExample) |
| CA (1) | CA2748235A1 (enExample) |
| CL (1) | CL2011001590A1 (enExample) |
| CO (1) | CO6450688A2 (enExample) |
| CR (1) | CR20110365A (enExample) |
| CU (1) | CU24017B1 (enExample) |
| DO (1) | DOP2011000205A (enExample) |
| EA (1) | EA201190064A1 (enExample) |
| EC (1) | ECSP11011161A (enExample) |
| GT (1) | GT201100186A (enExample) |
| HN (1) | HN2011001773A (enExample) |
| IL (1) | IL213518A0 (enExample) |
| MX (1) | MX2011006680A (enExample) |
| NI (1) | NI201100131A (enExample) |
| NZ (1) | NZ593282A (enExample) |
| PE (1) | PE20120249A1 (enExample) |
| SA (1) | SA109310013B1 (enExample) |
| SG (2) | SG171928A1 (enExample) |
| SV (1) | SV2011003962A (enExample) |
| TW (1) | TWI442922B (enExample) |
| UA (1) | UA106056C2 (enExample) |
| UY (1) | UY32360A (enExample) |
| WO (1) | WO2010074647A1 (enExample) |
| ZA (1) | ZA201105441B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110097996A (ko) * | 2008-12-24 | 2011-08-31 | 아스트라제네카 아베 | 에탄아민 화합물 및 우울증의 치료를 위한 그의 용도 |
| CN112279843B (zh) * | 2020-11-24 | 2023-05-16 | 深圳市第二人民医院(深圳市转化医学研究院) | 一种具有抗抑郁活性的含氮杂环化合物 |
| CN112250676B (zh) * | 2020-11-24 | 2023-05-16 | 深圳市第二人民医院(深圳市转化医学研究院) | 一种具有抗抑郁活性的含氧杂环化合物 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3422191A (en) | 1965-01-21 | 1969-01-14 | Synergistics Inc | Compositions and methods for tranquilization employing salts of n-morpholine ethanol |
| GB1427026A (en) | 1972-11-20 | 1976-03-03 | Ici Ltd | Synthetic film materials |
| JPS5756474B2 (enExample) | 1973-05-26 | 1982-11-30 | ||
| GB9320273D0 (en) | 1993-04-01 | 1993-11-17 | Fisons Corp | Compound useful in therapy |
| US5455259A (en) | 1987-02-06 | 1995-10-03 | Fisons Corporation | Compounds for the treatment of neurodegenerative disorders |
| ES2083972T3 (es) | 1988-08-12 | 1996-05-01 | Astra Ab | Arilalquil-aminas y -amidas con propiedades anticonvulsivas y neuroprotectoras. |
| JP2514855B2 (ja) | 1990-08-08 | 1996-07-10 | キッセイ薬品工業株式会社 | 光学活性なアラニンアニリド誘導体の酸付加塩 |
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| ES2142320T3 (es) | 1991-10-30 | 2000-04-16 | Astra Ab | Derivados de 2-pirazinil-etilamina y su uso como productos farmaceuticos. |
| NZ251384A (en) * | 1992-04-03 | 1996-10-28 | Fisons Corp | (s)-enantiomer of 1-phenyl-2-(2-pyridinyl) ethylamine and medicaments |
| DK0898566T3 (da) * | 1996-04-19 | 2003-03-03 | Akzo Nobel Nv | Substituerede benzylaminer og anvendelse deraf til behandling af depression |
| ATE229004T1 (de) | 1997-03-31 | 2002-12-15 | Korea Res Inst Chem Tech | Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung |
| TW544448B (en) | 1997-07-11 | 2003-08-01 | Novartis Ag | Pyridine derivatives |
| SE9901077D0 (sv) * | 1999-03-23 | 1999-03-23 | Astra Ab | Novel use |
| SE9901340D0 (sv) | 1999-04-15 | 1999-04-15 | Astra Pharma Prod | Novel process |
| DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
| KR20110097996A (ko) | 2008-12-24 | 2011-08-31 | 아스트라제네카 아베 | 에탄아민 화합물 및 우울증의 치료를 위한 그의 용도 |
-
2009
- 2009-12-22 KR KR1020117017236A patent/KR20110097996A/ko not_active Withdrawn
- 2009-12-22 EA EA201190064A patent/EA201190064A1/ru unknown
- 2009-12-22 SA SA109310013A patent/SA109310013B1/ar unknown
- 2009-12-22 US US12/644,046 patent/US8013165B2/en not_active Expired - Fee Related
- 2009-12-22 JP JP2011543474A patent/JP5491524B2/ja not_active Expired - Fee Related
- 2009-12-22 CN CN200980157411.9A patent/CN102333762B/zh not_active Expired - Fee Related
- 2009-12-22 SG SG2011040342A patent/SG171928A1/en unknown
- 2009-12-22 MX MX2011006680A patent/MX2011006680A/es active IP Right Grant
- 2009-12-22 UA UAA201107171A patent/UA106056C2/uk unknown
- 2009-12-22 WO PCT/SE2009/051493 patent/WO2010074647A1/en not_active Ceased
- 2009-12-22 BR BRPI0923476A patent/BRPI0923476A2/pt not_active IP Right Cessation
- 2009-12-22 SG SG2013053749A patent/SG192510A1/en unknown
- 2009-12-22 EP EP09835355A patent/EP2391606A4/en not_active Withdrawn
- 2009-12-22 NZ NZ593282A patent/NZ593282A/xx not_active IP Right Cessation
- 2009-12-22 CA CA2748235A patent/CA2748235A1/en not_active Abandoned
- 2009-12-22 PE PE2011001282A patent/PE20120249A1/es not_active Application Discontinuation
- 2009-12-22 AU AU2009330745A patent/AU2009330745B2/en not_active Ceased
- 2009-12-22 EP EP13159532.4A patent/EP2610246A1/en not_active Withdrawn
- 2009-12-23 TW TW098144591A patent/TWI442922B/zh not_active IP Right Cessation
- 2009-12-23 AR ARP090105104A patent/AR074981A1/es not_active Application Discontinuation
- 2009-12-23 UY UY0001032360A patent/UY32360A/es not_active Application Discontinuation
-
2011
- 2011-06-13 IL IL213518A patent/IL213518A0/en unknown
- 2011-06-24 GT GT201100186A patent/GT201100186A/es unknown
- 2011-06-24 HN HN2011001773A patent/HN2011001773A/es unknown
- 2011-06-24 SV SV2011003962A patent/SV2011003962A/es unknown
- 2011-06-24 DO DO2011000205A patent/DOP2011000205A/es unknown
- 2011-06-24 CU CU2011000141A patent/CU24017B1/es not_active IP Right Cessation
- 2011-06-24 NI NI201100131A patent/NI201100131A/es unknown
- 2011-06-24 EC EC2011011161A patent/ECSP11011161A/es unknown
- 2011-06-24 CR CR20110365A patent/CR20110365A/es unknown
- 2011-06-24 CL CL2011001590A patent/CL2011001590A1/es unknown
- 2011-06-29 CO CO11081454A patent/CO6450688A2/es not_active Application Discontinuation
- 2011-07-22 ZA ZA2011/05441A patent/ZA201105441B/en unknown
- 2011-08-29 US US13/219,892 patent/US20120115913A1/en not_active Abandoned
-
2012
- 2012-03-27 US US13/431,303 patent/US20120277272A1/en not_active Abandoned
-
2013
- 2013-01-24 US US13/748,852 patent/US9035065B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT4021901T (lt) | Pakeistieji piridopirimidinonilo junginiai, naudotini kaip t ląstelių aktyvatoriai | |
| CL2007003100A1 (es) | Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria. | |
| CY1109916T1 (el) | Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις | |
| BRPI0512792A (pt) | formas cristalinas sólidas de cloridrato de ( - ) - (1r, 2r) - 3 - (3-dimetilamino-1-etil-2-metilpropil) - fenol | |
| CY1111729T1 (el) | Υπογλωσσιο επικαλυμμενο δισκιο | |
| CY1111793T1 (el) | Μυκητοκτονες συνθεσεις | |
| ATE526318T1 (de) | Farnesoid-x-rezeptor-agonisten | |
| CY1117615T1 (el) | Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης | |
| CL2011003085A1 (es) | Compuestos derivados de 1-(piperidin-4-il)-pirazol, moduladores de la actividad del receptor acoplado a proteina g, gpr 119; composicion farmaceutica; uso de los compuestos en el tratamiento de la diabetes o de una morbilidad asociada con dicha diabetes. | |
| CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
| BRPI0813237A2 (pt) | Composto, método para preparar o composto, composição, medicamento, e, uso do composto. | |
| CL2011000191A1 (es) | Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer. | |
| GB2453058A (en) | Kinase antagonists | |
| TN2009000446A1 (en) | P70 s6 kinase inhibitors | |
| ATE530170T1 (de) | Paliperidonformulierung mit verzögerter freisetzung | |
| ATE430747T1 (de) | 2-pyrimidinyl-pyrazolopyridin-erbb- kinaseinhibitoren | |
| ECSP11011307A (es) | Comprimidos para terapia de combinacion | |
| CL2014003472A1 (es) | Pro-farmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)acrilamida; composicion farmaceutica que los comprende; y su uso para tratar una infeccion bacteriana. | |
| UY30306A1 (es) | Moduladores de mglur5 iii | |
| UY30307A1 (es) | Moduladores de mglur5 vi | |
| BRPI0813379A2 (pt) | Composto, composição farmacêutica, uso de um composto, e, método para modular atividade de um receptor de gabaa. | |
| BRPI0903914A2 (pt) | Uso de um composto, método para analisar a eficácia de uma composição de liberação prolongada, e, composição farmacêutica. | |
| CR11601A (es) | Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteina quinasa | |
| CL2007003817A1 (es) | Agente terapeutico para la miopatia inflamatoria que comprende un antagonista de interleucina-6 (il-6). | |
| CO6280510A2 (es) | Pirimidil ciclopentanos hidroxilados como inhibidores de akt proteina quinasa |